

Oncology Today with Dr Neil Love: Optimizing the Management of Endocrine-Resistant HR-Positive Metastatic Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Datopotamab deruxtecan is FDA approved in which of the following settings?
 - a. For metastatic triple-negative breast cancer (mTNBC) after 2 or more prior lines of therapy
 - b. In combination with pembrolizumab as first-line therapy for mTNBC
 - c. For HR-positive, HER2-positive metastatic breast cancer (mBC) after prior targeted therapy
 - d. For HR-positive, HER2-negative mBC after prior endocrine therapy and chemotherapy
2. What was the approximate reduction in the risk of disease progression or death with datopotamab deruxtecan in comparison to investigator's choice of chemotherapy for patients with previously treated HR-positive, HER2-negative breast cancer in the Phase III TROPION-Breast01 study?
 - a. 12%
 - b. 36%
 - c. 50%
 - d. 70%
3. Which of the following best describes outcomes with sacituzumab govitecan versus treatment of physician's choice for patients with advanced HR-positive, HER2-negative breast cancer in the Phase III TROPiCS-02 trial?
 - a. No improvement in progression-free survival (PFS) or overall survival (OS)
 - b. Significant improvement in PFS only
 - c. Significant improvement in PFS and OS
4. Emiltatug ledadotin is an investigational antibody-drug conjugate targeting...
 - a. HER3
 - b. LIV-1
 - c. TROP2
 - d. B7-H4
5. How is HER2-ultralow breast cancer defined?
 - a. HER2 IHC 1+ or 2+
 - b. HER2 IHC 1+
 - c. HER2 IHC 0 with $\leq 1\%$ staining
 - d. HER2 IHC 0 with $\leq 5\%$ staining
 - e. HER2 IHC 0 with $\leq 10\%$ staining